Zacks Research Has Pessimistic Outlook of AXSM Q1 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Zacks Research lowered their Q1 2027 earnings estimates for shares of Axsome Therapeutics in a report issued on Tuesday, July 1st. Zacks Research analyst R. Department now anticipates that the company will earn $0.42 per share for the quarter, down from their prior forecast of $0.43. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share.

Several other equities analysts have also recently issued reports on the company. Mizuho raised their price target on Axsome Therapeutics from $212.00 to $216.00 and gave the company an "outperform" rating in a report on Thursday, March 27th. Wells Fargo & Company restated an "overweight" rating and set a $165.00 price objective (up from $160.00) on shares of Axsome Therapeutics in a report on Tuesday, May 6th. Needham & Company LLC cut their price target on shares of Axsome Therapeutics from $153.00 to $150.00 and set a "buy" rating on the stock in a research report on Monday, June 9th. HC Wainwright restated a "buy" rating and set a $180.00 price objective on shares of Axsome Therapeutics in a research note on Tuesday, June 10th. Finally, Jefferies Financial Group began coverage on Axsome Therapeutics in a report on Monday, April 7th. They issued a "buy" rating and a $200.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $172.33.

Axsome Therapeutics Trading Up 0.9%

Shares of NASDAQ AXSM traded up $0.94 during midday trading on Wednesday, hitting $103.91. The stock had a trading volume of 399,410 shares, compared to its average volume of 669,228. The firm has a market cap of $5.12 billion, a P/E ratio of -18.01 and a beta of 0.46. Axsome Therapeutics has a fifty-two week low of $72.21 and a fifty-two week high of $139.13. The company has a debt-to-equity ratio of 3.48, a current ratio of 2.03 and a quick ratio of 1.96. The company's 50-day simple moving average is $106.66 and its 200 day simple moving average is $107.39.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of AXSM. Meridian Wealth Management LLC increased its stake in Axsome Therapeutics by 0.7% in the 4th quarter. Meridian Wealth Management LLC now owns 21,171 shares of the company's stock valued at $1,791,000 after buying an additional 150 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Axsome Therapeutics by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 328,034 shares of the company's stock valued at $27,755,000 after acquiring an additional 5,438 shares during the last quarter. Torray Investment Partners LLC lifted its holdings in Axsome Therapeutics by 45.3% during the fourth quarter. Torray Investment Partners LLC now owns 17,174 shares of the company's stock worth $1,453,000 after acquiring an additional 5,351 shares during the period. Assetmark Inc. purchased a new position in Axsome Therapeutics in the fourth quarter worth $52,000. Finally, Aigen Investment Management LP bought a new position in Axsome Therapeutics in the 4th quarter valued at $395,000. Hedge funds and other institutional investors own 81.49% of the company's stock.

Insider Activity at Axsome Therapeutics

In related news, General Counsel Hunter R. Murdock sold 6,014 shares of the stock in a transaction on Monday, June 23rd. The stock was sold at an average price of $100.12, for a total value of $602,121.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Mark Coleman sold 3,750 shares of the firm's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $105.47, for a total transaction of $395,512.50. Following the completion of the transaction, the director directly owned 50,387 shares in the company, valued at approximately $5,314,316.89. The trade was a 6.93% decrease in their position. The disclosure for this sale can be found here. Insiders sold 93,437 shares of company stock valued at $9,834,215 in the last three months. Corporate insiders own 22.40% of the company's stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.